Innovative Oncology Focus Kestrel Therapeutics is dedicated to developing targeted treatments for cancer, specifically focusing on potent inhibitors of pan-oncogenic-RAS. This specialization indicates opportunities to collaborate with biotechnology firms and clinical research organizations involved in cancer precision medicine.
Growing Financial Profile With annual revenue estimated between 10 and 25 million dollars, Kestrel shows promising financial growth potential, suggesting they may be open to strategic investments, partnerships, or service contracts to accelerate their R&D efforts.
Technology Utilization The company's tech stack includes advanced tools like PyTorch and robust programming languages, highlighting their reliance on cutting-edge AI and computational methods. This presents opportunities for software vendors, AI service providers, and technological collaborators.
Collaborative Potential Kestrel's focus on innovative molecule discovery and development positions them well for partnerships with contract research organizations, biotech suppliers, and academic institutions to enhance their research pipeline and clinical trial capabilities.
Market Positioning As a small, agile company competing with larger biotech firms, Kestrel may be receptive to tailored services and solutions that support startup growth, such as customized consulting, funding assistance, or specialized laboratory services.
$50M$100M
$100M$250M
$10M$25M
$100M$250M
$25M$50M
$1M$10M
$1M$10M
$250M$500M
$1M$10MKestrel Therapeutics uses 8 technology products and services including JSON-LD, jQuery, PyTorch, and more. Explore Kestrel Therapeutics's tech stack below.
| Kestrel Therapeutics Email Formats | Percentage |
| First.Last@kestreltherapeutics.com | 48% |
| FirstMiddleLa@kestreltherapeutics.com | 2% |
| First.Last@kestreltherapeutics.com | 48% |
| FirstMiddleLa@kestreltherapeutics.com | 2% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
Our goal is to bring new therapy to cancer’s most frequently mutated oncogenic target. Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS. We rely on exceptional science, and our focus, always, is on patients.
Company Overview
Funding & FinancialsKestrel Therapeutics's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsKestrel Therapeutics's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com